THE QUERY LEDGER · 25 QUESTIONS
BPC-157 TB-500 FAQ: Twenty-Five Questions, Answered from the Record
Definitional, mechanistic, efficacy, dosing, safety, and regulatory questions about the Wolverine blend — each answered directly and cited to the literature or the FDA record.
What the blend is
BPC-157 TB-500 is the two-peptide Wolverine blend, and this ledger answers the most common questions about it from the published record. The definitional ones come first.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and most TB-500 efficacy data come from full-length Thymosin Beta-4 rather than the marketed fragment [4] [5].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide, the cytoprotective and angiogenic component; TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4, the cytoskeletal and cell-migration component [3]. The Wolverine blend pairs the two, and neither is an FDA-approved drug.
What is the BPC-157 and TB-500 blend used for in research?
In animal models the constituents have been studied for tendon, ligament, muscle, and wound repair [1] [4]. All efficacy data are preclinical and single-compound, not from the blend in humans, and no controlled combination study exists [7].
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-mer derived from a gastric-juice protein, acting via VEGFR2-Akt-eNOS [2]; TB-500 is a 7-mer fragment of Thymosin Beta-4 acting via G-actin sequestration [3]. They differ in structure, size, and mechanism.
Why they are combined, and how they work
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms — BPC-157 supplies a local angiogenic and cytoprotective signal while TB-500 supplies an actin-sequestration and cell-migration signal — but this synergy is a theoretical extrapolation, not a finding from a controlled combination study [7].
How does BPC-157 work compared to TB-500?
BPC-157 acts as a local angiogenic and cytoprotective signal, up-regulating VEGFR2 with downstream Akt-eNOS [2], whereas TB-500 acts intracellularly by sequestering G-actin [3]. The pathways are largely non-overlapping.
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it — structurally confirmed for Thymosin Beta-4 by 2 A crystallography [3] — regulating the cytoskeletal dynamics that drive cell migration.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
In animal and in-vitro models, BPC-157 is pro-angiogenic via VEGFR2 up-regulation and Akt-eNOS signaling [2]; thymosin beta-4 promotes angiogenesis by endothelial migration [4]. Both are preclinical mechanisms.
Evidence and efficacy
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together; the 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use [7].
Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled clinical trials of the combination for any indication [7]. Human data exist only for the individual constituents and are themselves thin — BPC-157 has three small pilot studies [9], and human "TB-500" data are for full-length Thymosin Beta-4 [5].
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical and microscopic measures in animal studies [1]. These are preclinical, single-compound findings, not blend efficacy in humans.
Does BPC-157 and TB-500 help muscle tears and recovery?
A 2025 systematic review found BPC-157 "shows promise" for musculoskeletal recovery, but only from the lowest tiers of evidence (level IV-V) and with no clinical safety data [7]; no human blend data exist.
Does the BPC-157 TB-500 blend help wound healing?
Thymosin beta-4 accelerated re-epithelialization and collagen deposition in animal wound models and reduced myofibroblast number, meaning less scarring [4]. These are single-compound preclinical findings, not blend data in humans.
Dosing context
What is the half-life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported as under 30 minutes in animal pharmacokinetics [1]. No validated human half-life exists for either constituent at research doses, and none for the blend [5].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated; product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [5]. This describes research handling, not a human preparation instruction.
How often should you inject BPC-157 and TB-500?
There is no validated dosing schedule for the blend; community "loading then maintenance" protocols have no controlled-trial basis [8]. Research doses are reported per body weight in animal models only [1] [4].
How do you cycle BPC-157 and TB-500?
No validated cycling protocol exists; fixed-ratio vials (for example 10 mg + 10 mg) and loading/maintenance schedules circulate in the community without any controlled human-trial basis [8], and the one dose-response study available shows the highest dose can give no benefit [4].
Safety
What are the side effects of BPC-157 and TB-500?
There is no controlled human safety dataset for the blend. Reviews note that rigorous human safety data are scarce, with potential for serious harm, and the combination's safety is unproven [8]; a 2025 BPC-157 systematic review found no clinical safety data [7].
Does TB-500 cause cancer or promote tumor growth?
Thymosin beta-4 is implicated in tumor angiogenesis and metastasis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is an unresolved safety consideration drawn from the mechanism, not a demonstrated clinical effect of the blend.
Is the BPC-157 / TB-500 blend safe for long-term use?
Long-term human safety is unknown. BPC-157 has only three small human pilot studies [9], the TB-500 fragment has no completed controlled human trials [5], and the combination has never been studied long-term [7].
Is TB-500 bad for your heart?
There is no validated human cardiac-safety data for TB-500 or the blend. Thymosin beta-4's vascular and migratory effects are studied preclinically [4], and 2025-2026 reviews stress that human safety data for these unapproved peptides are scarce [8]. The cardiac question is open, not answered.
Regulatory and access
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use, and the blend has no approved indication; FDA placed both components in 503A Category 2 of bulk substances flagged for significant safety risks, effective with the September 29, 2023 update [10]. Both are also WADA-prohibited — BPC-157 under S0 non-approved substances, TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories.
Is Wolverine legal?
Status depends on jurisdiction and context. Neither constituent is an FDA-approved medicine, both are currently 503A Category 2 bulk substances restricting pharmacy compounding access while that status stands [10] [11], and both are WADA-prohibited in sport. See the Wolverine legal status and FDA 503A compounding access page for the full record.
Can you get BPC-157 from a compounding pharmacy?
Under current FDA status, routine 503A pharmacy compounding of BPC-157 is restricted: FDA placed it in Category 2, outside the enforcement-discretion policy, effective with the September 29, 2023 list update [10]. BPC-157 is on the PCAC agenda for July 23-24, 2026 as a bulks-list candidate — a scheduled discussion, not a change in status [12].
What is the FDA 503A status of Wolverine?
The blend is not an approved drug; both components are in FDA's 503A Category 2, placed there effective with the September 29, 2023 update, and both appear on the July 23-24, 2026 PCAC agenda as candidates under evaluation for the 503A bulks list [10] [12].